GlassScriptPhysician profile
Jessica Lam
NPI 1114451382
$7,682.16
in general payments reported to CMS, 2019-2025
12 companies · $252 in 2025
The $252 reported for 2025 was less than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $137 · 2023: $5,042 · 2024: $2,251 · 2025: $252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,000 · Travel and Lodging: $2,153 · Food and Beverage: $1,384 · Gift: $8.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,000.00 |
| Travel and Lodging | $2,152.79 |
| Food and Beverage | $1,383.62 |
| Gift | $8.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $5,231.18 | 2023-2024 | Davinci Xi, Da Vinci Surgical System |
| Medtronic, INC. | $1,195.46 | 2023-2025 | Interstim |
| Thd America, INC. | $863.69 | 2023-2025 | |
| Medical Device Business Services, INC. | $137.01 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $79.66 | 2024-2025 | Gattex |
| Baxter Healthcare | $28.88 | 2024 | Perclot, Tisseel |
| Ethicon US, LLC | $28.46 | 2024 | Echelon Circular |
| Vertex Pharmaceuticals Incorporated | $28.27 | 2025 | |
| Braintree Laboratories, INC. | $26.39 | 2025 | Sutab, Suflave |
| Innovation Technologies INC | $26.01 | 2025 | Irrisept |
| Solventum Corporation | $19.61 | 2024 | V.A.C. Veraflo, Prevena |
| Inspire Medical Systems, INC. | $17.54 | 2025 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Lam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.